Buparlisib

DB11666InvestigationalSmall molecule

Buparlisib has been used in trials studying the treatment and basic science of Lymphoma, Metastases, Lung Cancer, Solid Tumors, and Breast Cancer, among others.

Chemical structure of Buparlisib
Formula / weight
C18H21F3N6O2 · 410.3935 g/mol (avg)
Code names
BKM-120 · BKM-120NX · NVP-BKM-120

Resolves to

Compound
UNII0ZM2Z182GDCAS944396-07-0ChEMBLCHEMBL2017974ChEBI71954PubChem16654980
Structure
InChIKeyCWHUFRVAEUJCEF-UHFFFAOYSA-NSMILESNC1=CC(=C(C=N1)C1=NC(=NC(=C1)N1CCOCC1)N1CCOCC1)C(F)(F)F
Targets
P42336PIK3CAP42338PIK3CBP48736PIK3CGO00329PIK3CD

What you can answer from here — as of September 11, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
81Clinical trialsPhase, status and sponsor resolved per trial
Sign in
16+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Buparlisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In